ライフサイエンスコーパス: lumpectomy

1 correlated with the presence of carcinoma at lumpectomy.

2 s with a less than 2% chance of carcinoma at lumpectomy.

3 ng surgical accuracy and margin status after lumpectomy.

4 clinical or mammographic findings following lumpectomy.

5 gement of breast tumors judged too large for lumpectomy.

6 hy to allow accurate needle localization for lumpectomy.

7 permitted successful needle localization and lumpectomy.

8 s per timing of randomisation in relation to lumpectomy.

9 eceptor-negative cancer, and radiation after lumpectomy.

10 for any type of esophageal cancer following lumpectomy.

11 (0.66%) when compared with women that had a lumpectomy (0.14%).

12 After lumpectomy, 1,009 women were randomly assigned to TAM (n

13 Tumor sites were excised at lumpectomy 2-3 weeks after cryoablation.

14 cancer patients were more likely to undergo lumpectomy (67% vs 48% of Pt/PhysD breast cancer patient

15 After lumpectomy 6952 patients were treated with brachytherapy

16 aspiration (19/59), core biopsy (39/59), or lumpectomy (8/59) underwent SLN localization.

17 Of those women who underwent lumpectomy, 86% had subsequent radiation.

18 ; 87% clinical tumor size < or = 2.0 cm; 84% lumpectomy; 87% white).

19 In patients who had a lumpectomy, a high body mass index, smoking, and a histo

20 The greatest increase in lumpectomy after preoperative therapy occurred in women

21 ral breast recurrence were 7.8% and 7.8% for lumpectomy alone and 8.0% and 9.2% for lumpectomy + RT,

22 hat the combination was more beneficial than lumpectomy alone for localized intraductal carcinoma-in-

23 th radiation therapy was more effective than lumpectomy alone for the treatment of ductal carcinoma i

24 ctomy plus radiation is more beneficial than lumpectomy alone for women with localized, mammographica

25 Median follow-up was 5.9 years for the lumpectomy alone group and 7.2 years for the lumpectomy

26 ate of TR/MM in both the lumpectomy + RT and lumpectomy alone groups.

27 ble Stage IA and IB cancer with 26.6% having lumpectomy alone versus 9.4% in the younger patients.

28 reated by lumpectomy and radiation, 30.2% by lumpectomy alone, and 2.6% with no surgery.

29 atio for death among the women who underwent lumpectomy alone, as compared with those who underwent t

30 ed treatment consisting of total mastectomy, lumpectomy alone, or lumpectomy and breast irradiation.

31 However, for patients treated with lumpectomy alone, the number of surgical procedures and

32 sses, and overall for patients who underwent lumpectomy alone.

33 f whom 46,250 (62.1%) underwent a completion lumpectomy and 28,267 (37.9%) underwent a mastectomy.

34 >F or CMF after lumpectomy and breast irradiation resulted in a low prob

35 was 14.3 percent in the women who underwent lumpectomy and breast irradiation, as compared with 39.2

36 ng of total mastectomy, lumpectomy alone, or lumpectomy and breast irradiation.

37 antified from diffuse reflectance spectra of lumpectomy and mastectomy specimens using a Monte Carlo

38 Twelve patients underwent lumpectomy and postsurgical intraoperative supine MR ima

39 e breast cancer were more often treated with lumpectomy and radiation and underwent fewer mastectomie

40 ve breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamox

41 reoperatively than postoperatively underwent lumpectomy and radiation therapy (67.8% v 59.8%, respect

42 cancer patients treated conservatively with lumpectomy and radiation therapy (LRT) have an estimated

43 th stages I to II breast cancer treated with lumpectomy and radiation therapy (median follow-up, 12.1

44 ral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy (P = 0.001).

45 osis on the outcome of treatment with either lumpectomy and radiation therapy (RT) or mastectomy for

46 rapy, and tamoxifen was of more benefit than lumpectomy and radiation therapy alone for DCIS.

47 Lumpectomy and radiation therapy in patients with breast

48 with early-stage breast cancer treated with lumpectomy and radiation therapy, 30% to 40% will develo

49 ammograms during follow-up of patients after lumpectomy and radiation therapy.

50 without complications underwent ipsilateral lumpectomy and radiation therapy.

51 In 1992, 23.3% of cases were treated by lumpectomy and radiation, 30.2% by lumpectomy alone, and

52 s with ductal carcinoma in situ (DCIS) after lumpectomy and radiation.

53 ate follow-up, younger patients treated with lumpectomy and RT had a significantly higher rate of loc

54 sis on the outcome of treatment of DCIS with lumpectomy and RT or mastectomy were identified through

55 treatment of younger patients with DCIS with lumpectomy and RT requires careful attention to patient

56 DCIS, the influence of age on outcome after lumpectomy and RT, and the impact of age on outcome afte

57 l rates if treated by mastectomy rather than lumpectomy and RT.

58 n with clinical T1-2,N0,M0 disease underwent lumpectomy and SLN dissection.

59 negative lymph nodes who were candidates for lumpectomy and SLND.

60 All patients underwent lumpectomy and tangential whole-breast irradiation.

61 ine negative or close surgical margins after lumpectomy and to determine the factors that govern the

62 ident early-stage breast cancer treated with lumpectomy and WBI from 2008 and 2013 into 2 cohorts: (1

63 with clinically negative nodes, planned for lumpectomy and whole breast irradiation.

64 Lumpectomy and whole-breast radiotherapy (ie, breast-con

65 nts, 43% underwent mastectomy, 53% underwent lumpectomy, and therapy of 4% of patients is unknown.

66 The only discrete palpable finding was lumpectomy bed seroma.

67 omen with tumors less than 5 cm were already lumpectomy candidates.

68 eloped within or immediately adjacent to the lumpectomy cavity and were designated as true recurrence

69 valuate the worth of radiation therapy after lumpectomy concluded that the combination was more benef

70 ir physicians approach the mastectomy versus lumpectomy decision.

71 asing risk of systemic relapse, frequency of lumpectomy declined (rates for five strata in order of i

72 Surgery after initial lumpectomy declined by 16% (P < .001).

73 Additional surgery after initial lumpectomy decreased markedly from 2013 to 2015 concomit

74 Lumpectomy followed by breast irradiation continues to b

75 atio for death among the women who underwent lumpectomy followed by breast irradiation, as compared w

76 agnosed at age 42 years or younger underwent lumpectomy followed by radiotherapy at our hospital.

77 Lumpectomy followed by radiotherapy provides an appealin

78 early-stage breast cancer were managed with lumpectomy followed by RT restricted to the tumor bed us

79 lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy.

80 nized cytotoxic therapy before mastectomy or lumpectomy for advanced breast carcinoma, 56 were select

81 Just as lumpectomy for breast cancer aims at achieving oncologic

82 ent years, use of breast brachytherapy after lumpectomy for early breast cancer has increased substan

83 endly mode for delivering radiotherapy after lumpectomy for early breast cancer.

84 ns who recognise the limitations of standard lumpectomy for large breast cancers, and review differen

85 Two groups of women undergoing lumpectomy for palpable breast cancer were studied, one

86 ummarise the general approach to oncoplastic lumpectomy for surgeons who recognise the limitations of

87 ved adjuvant whole-breast radiotherapy after lumpectomy for unilateral breast cancer at MROQC partici

88 o 43.8%) and an increase in those treated by lumpectomy (from 25.6% to 53.3%).

89 g in the mastectomy (4.34%) group versus the lumpectomy group (1.97%).

90 e mastectomy group and 3.2 +/- 1.6 cm in the lumpectomy group (P = 0.0001).

91 no cardiac or pulmonary complications in the lumpectomy group.

92 he risk following breast-conserving surgery (lumpectomy) has yet to be determined.

93 ing treatment, various radiation doses after lumpectomy have been used.

94 about the need for breast irradiation after lumpectomy in node-negative women with invasive breast c

95 The 67% rate of initial lumpectomy in the 3729 patient analytic sample was uncha

96 The rate of final lumpectomy increased by 13% from 2013 to 2015, accompani

97 uch people for whom further treatment beyond lumpectomy is not needed).

98 as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certai

99 owing M-->F versus 13.4% in women treated by lumpectomy; it was 0.6% following CMF in B-19.

100 /control status and by case treatment group: lumpectomy, lumpectomy with adjuvant radiation therapy,

101 me, and surgeon attitudes toward an adequate lumpectomy margin.

102 Lumpectomy margins in breast conserving operations durin

103 and one underwent excision but had tumor at lumpectomy margins.

104 y 2016, 488 surgeons were surveyed regarding lumpectomy margins; 342 (70%) responded completely.

105 2.1-4.0 cm, >/= 4.1 cm), and surgical plan (lumpectomy, mastectomy).

106 cipants eligible for radiation therapy after lumpectomy, navigated participants (n = 255) were no mor

107 Lumpectomy of pure LN lesions may not prevent malignancy

108 cidental microscopic findings at the time of lumpectomy or core-needle biopsy.

109 cal adipose deficiency, such as lipoatrophy, lumpectomy or facial trauma, is a formidable challenge i

110 ith localized DCIS were randomly assigned to lumpectomy or lumpectomy plus radiation (50 Gy).

111 METHODS After lumpectomy or mastectomy, women 60 years of age or young

112 patients immediately before their scheduled lumpectomy or mastectomy.

113 prepathology stratum, TARGIT concurrent with lumpectomy) or after lumpectomy (postpathology stratum,

114 nd rates of additional surgery after initial lumpectomy over time, and surgeon attitudes toward an ad

115 Lumpectomy patients received breast radiotherapy alone;

116 Independent predictors of LRR in lumpectomy patients were age, clinical nodal status (bef

117 All patients had planned lumpectomy, planned tangential whole-breast irradiation,

118 Lumpectomy plus adjuvant therapy with tamoxifen alone is

119 ts (8.9% local; 3.4% regional) and 10.3% for lumpectomy plus breast radiotherapy patients (8.1% local

120 DCIS were randomly assigned to lumpectomy or lumpectomy plus radiation (50 Gy).

121 w-up, our findings continue to indicate that lumpectomy plus radiation is more beneficial than lumpec

122 The benefit of lumpectomy plus radiation was virtually unchanged betwee

123 men with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.

124 e early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy

125 TARGIT concurrent with lumpectomy) or after lumpectomy (postpathology stratum, TARGIT given subseque

126 herapy: randomisation occurred either before lumpectomy (prepathology stratum, TARGIT concurrent with

127 TARGIT concurrently with lumpectomy (prepathology, n=2298) had much the same resu

128 Recurrent tumors that occurred in the lumpectomy quadrant were more often similar in mammograp

129 involved with tumour, were randomly assigned lumpectomy, radiation therapy (50 Gy), and placebo (n=90

130 ion therapy (50 Gy), and placebo (n=902), or lumpectomy, radiation therapy, and tamoxifen (20 mg dail

131 The combination of lumpectomy, radiation therapy, and tamoxifen was effecti

132 domised controlled trial to find out whether lumpectomy, radiation therapy, and tamoxifen was of more

133 -negative breast cancer who are treated with lumpectomy, radiation, and adjuvant systemic therapy, th

134 tive sentinel lymph nodes (SLNs) who undergo lumpectomy, radiotherapy (RT), and systemic therapy.

135 Among patients who received lumpectomy, radiotherapy was associated with a reduction

136 Lumpectomy rates were analyzed within study-defined risk

137 factors were independent predictors of lower lumpectomy rates, prospective research is needed into ho

138 gnificantly higher rate of TR/MM in both the lumpectomy + RT and lumpectomy alone groups.

139 lumpectomy alone group and 7.2 years for the lumpectomy + RT group.

140 % for lumpectomy alone and 8.0% and 9.2% for lumpectomy + RT, respectively.

141 Radiotherapy (RT) after lumpectomy significantly reduces the risk of recurrence.

142 eveloped microcalcifications confined to the lumpectomy site after more than 3 years.

143 rrences, 19 (70%) were at or adjacent to the lumpectomy site and eight (30%) were elsewhere in the br

144 appearing microcalcifications develop at the lumpectomy site depending on time of appearance and numb

145 < or = 3 mm were more frequently found, and lumpectomy site radiation boost was used increasingly fr

146 east local recurrence away from the original lumpectomy site with or without postoperative standard w

147 eveloped microcalcifications confined to the lumpectomy site.

148 tumor bed, for a total dose of 48 Gy to the lumpectomy site.

149 The pathology of the lumpectomy specimen was reviewed for each patient to con

150 were compared with histologic findings from lumpectomy specimens to determine presence of intraducta

151 Of these lumpectomy specimens, 11 were identified with a positive

152 lcifications at the resection margins of the lumpectomy specimens, but had negative microscopic margi

153 gions were acquired from surgical margins of lumpectomy specimens, registered with ink, and correlate

154 Patients treated by lumpectomy that received RT had a superior OS compared w

155 the use of intraoperative irradiation after lumpectomy, the management of ductal carcinoma the effec

156 cm, IBTR occurs with enough frequency after lumpectomy to justify considering XRT, regardless of tum

157 Surgery after initial lumpectomy to obtain more widely clear margins is common

158 eceptor-positive breast carcinoma treated by lumpectomy to receive tamoxifen plus radiation therapy (

159 Among the lumpectomy-treated women whose surgical specimens had tu

160 Rates of final surgical procedure (lumpectomy, unilateral mastectomy, bilateral mastectomy)

161 ctomy (US dollars 2775 v US dollars 1849) or lumpectomy (US dollars 2112 v US dollars 1365) was used.

162 Significant predictors of lower lumpectomy usage were determined in multivariate analyse

163 Lumpectomy use declined with increasing tumor size and d

164 he following significant predictors of lower lumpectomy use: positive nodes; many positive nodes, inc

165 gram receipt were higher for women who had a lumpectomy (v mastectomy) and women who were white (v no

166 Younger or older age, lumpectomy (v mastectomy), and comorbidities were associ

167 Before randomization, lumpectomy was proposed for 86% of women with tumors < o

168 itial implant, and lasting 4 to 5 days after lumpectomy was prospectively evaluated in early-stage br

169 Overall, 12% more lumpectomies were performed in the preoperative group; i

170 Similarly, the rates of re-excision lumpectomy were also significantly lower during the B pe

171 r (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen p

172 who were candidates for either mastectomy or lumpectomy were recruited from a university breast cance

173 lateral breast tumor recurrence (IBTR) after lumpectomy were similar in both groups (7.9% and 5.8%, r

174 241,597 patients (76.4%) underwent a single lumpectomy, whereas 74,517 (23.6%) underwent at least 1

175 B-18, B-22, and B-25), who were treated with lumpectomy, whole-breast irradiation, and adjuvant syste

176 ts who underwent radiation therapy following lumpectomy with a planned electron boost were examined.

177 Eighty-five patients treated with BCT (lumpectomy with adjuvant radiation therapy) at the Medic

178 tus and by case treatment group: lumpectomy, lumpectomy with adjuvant radiation therapy, and mastecto

179 for all women undergoing mastectomy (MT) or lumpectomy with an axillary procedure (L-ANP).

180 n in patients treated by mastectomy (80%) or lumpectomy with axillary dissection and radiation (95%,

181 Two women underwent lumpectomy with breast irradiation.

182 positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole breast

183 positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole-breast

184 ast cancer who had undergone a mastectomy or lumpectomy with clear surgical margins.

185 ated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effe

186 Case participants who underwent lumpectomy with radiation reported lower levels of emoti

187 We have shown previously that lumpectomy with radiation therapy was more effective tha

188 She underwent a left lumpectomy with seed localization and sentinel lymph nod

189 and 22 mastectomy candidates were changed to lumpectomy, with tumor size decreasing from 4.2 +/- 2.1

190 TARGIT concurrent with lumpectomy within a risk-adapted approach should be cons

191 However, for patients undergoing lumpectomy without axillary surgery, it is an extra inva

192 with 39.2 percent in the women who underwent lumpectomy without irradiation (P<0.001).

193 receipt (only 45.0% in patients who received lumpectomy without radiotherapy).